[1] |
Ding Y, Chu C, Li Y, et al. High expression of HMGB1 in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2018, 18:439.
doi: 10.1186/s12879-018-3346-8
|
[2] |
Meyer Sauteur PM, van Rossum AM, Vink C. Mycoplasma pneumoniae in children: carriage, pathogenesis, and antibiotic resistance[J]. Curr Opin Infect Dis, 2014, 27(3):220-227.
doi: 10.1097/QCO.0000000000000063
|
[3] |
Jiang ZL, Li SH, Zhu CM, et al, Mycoplasma pneumoniae infections: pathogenesis and vaccine development[J]. Pathogens, 2021, 10(2):119.
doi: 10.3390/pathogens10020119
|
[4] |
Tamura A, Matsubara K, Tanaka T, et al. Methyl-prednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children[J]. J Infect, 2008, 57(3):223-228.
|
[5] |
卢志威, 赵辉, 郑跃杰, 等. 三种方法对儿童肺炎支原体感染诊断的动态评价[J]. 临床儿科杂志, 2012, 30(4):382-385.
|
[6] |
Zhu Y, Wang J. Logistic regression analysis of high risk factors of mycoplasma pneumoniae pneumonia in children[J]. Hebei Med, 2018, 24:60-63.
|
[7] |
Qu BN, Chi L, Zhu ZW, et al. Clinical characteristics and high risk factors of mycoplasma pneumoniae pneumonia in children[J]. Chin Pediatr Integrated Traditi Western Med, 2019, 11:58-62.
|
[8] |
Liu XM, Cui ZZ, Yang G, et al. Analysis of risk factors of Mycoplasma pneumoniae pneumonia[J]. China J Modern Med, 2019, 10:1-8.
|
[9] |
Gong Hui, Sun Baijun, Chen Ye, et al. The risk factors of children acquiring refractory mycoplasma pneumoniae pneumonia: a meta-analysis[J]. Medicine (Baltimore), 2021, 100:e24894.
doi: 10.1097/MD.0000000000024894
|
[10] |
Liu XF, Zhao ZM, Zhang ZP, et al. Analysis of risk factors of Mycoplasma pneumoniae pneumonia in children[J]. Hebei Med, 2017, 23:780-783.
|
[11] |
Zhou YA. Changes of C-reactive protein in the course of mycoplasma pneumonia and its clinical significance[J]. Chin J Misdiagnosis, 2011, 11:3567-3569.
|
[12] |
Wen J, Su Y, Sun H, et al. The combination of initial markers to predict refractory Mycoplasma pneumoniae pneumonia in Chinese children: a case control study[J]. Respir Res, 2021, 22(1):89.
doi: 10.1186/s12931-020-01577-9
|
[13] |
Yuan SJ, Xie HT, Li ZL. Clinical significance of hypersensitive C-reactive protein, fribrinogen and D-dimmer in connective tissue disease-related interstitial lung disease[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2017, 37:415-419.
|
[14] |
Kazama I, Nakajima T. Acute bronchitis caused by bordetella pertussis possibly co-infected with Mycoplasma Pneumoniae[J]. Am J Case Rep, 2019, 20:60-64.
doi: 10.12659/AJCR.913430
|
[15] |
Tezol O, Bozlu G, Sagcan F, et al. Value of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio and red blood cell distribution width in distinguishing between reactive lymphadenopathy and lymphoma in children[J]. Bratisl Lek Listy, 2020, 121:287-292.
|
[16] |
Balta S, Demirkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice[J]. Hemodial Int, 2013, 17:668-669.
|
[17] |
Patel N, Penkert RR, Jones BG, et al. Baseline serum vitamin A and D levels determine benefit of oral vitamin A&D supplements to humoral immune responses following pediatric influenza vaccination[J]. Viruses, 2019, 11(10):907.
doi: 10.3390/v11100907
|
[18] |
Ling Y, Ning J, Xu Y. Explore the predictive value of peripheral blood cell parameters in refractory mycoplasma pneumoniae pneumonia in children over 6 years old[J]. Front Pediatr, 2021, 9:659677.
doi: 10.3389/fped.2021.659677
|
[19] |
Huang X, Li D, Liu F, et al. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infectious Diseases, 2021, 21(1):14.
doi: 10.1186/s12879-020-05700-5
pmid: 33407216
|
[20] |
Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children[J]. N Engl J Med, 2015, 372(9):835-845.
doi: 10.1056/NEJMoa1405870
|
[21] |
Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016[J]. Epidemiol Infect, 2019, 147:e192.
doi: 10.1017/S0950268819000839
|
[22] |
Zhang Y, Zhou Y, Li S, et al. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children[J]. PLoS One, 2016, 11(5):e0156465.
doi: 10.1371/journal.pone.0156465
|
[23] |
Bi Y, Zhu Y, Ma X, et al. Development of a scale for early prediction of refractory Mycoplasma pneumoniae pneumonia in hospitalized children[J]. Sci Rep, 2021, 11(1):6595.
doi: 10.1038/s41598-021-86086-5
|
[24] |
Zhao Q, Zhang T, Zhu B, et al. Increasing age affected polymorphonuclear neutrophils in prognosis of Myco-plasma pneumoniae pneumonia[J]. J Inflamm Res, 2021, 14:3933-3943.
doi: 10.2147/JIR.S321656
|
[25] |
Daxboeck F, Gattringer R, Mustafa S, et al. Elevated serum alanine aminotransferase (ALT) levels in patients with serologically verified Mycoplasma pneumoniae pneumonia[J]. Clin Microbiol Infect, 2010, 11(6):507-510.
doi: 10.1111/j.1469-0691.2005.01154.x
|
[26] |
Xu Q, Zhang L, Hao C, et al. Prediction of bronchial mucus plugs formation in patients with refractory Mycoplasma pneumoniae pneumonia[J]. J Trop Pediatr, 2017, 63(2):148-154.
|
[27] |
Xu X, Li H, Sheng Y, et al. Nomogram for prediction of bronchial mucus plugs in children with Mycoplasma pneumoniae pneumonia[J]. Sci Rep, 2020, 10(1):4579.
doi: 10.1038/s41598-020-61348-w
|
[28] |
Smeijsters KMG, Bijkerk RM, Daniels JMA, et al. Effect of bronchoscopy on gas exchange and respiratory mechanics in critically ill patients with atelectasis: an observational cohort study[J]. Front Med, 2018, 5:301.
doi: 10.3389/fmed.2018.00301
|
[29] |
Kavaliunaite E, Aurora P. Diagnosing and managing bronchiolitis obliterans in children[J]. Expert Rev Respir Med, 2019, 13(5):481-488.
doi: 10.1080/17476348.2019.1586537
|
[30] |
Cheng Q, Zhang H, Shang Y, et al. Clinical features and risk factors analysis of bronchitis obliterans due to refractory Mycoplasma pneumoniae pneumonia in children: a nomogram prediction model[J]. BMC Infect Dis, 2021, 21(1):1085.
doi: 10.1186/s12879-021-06783-4
pmid: 34674642
|